Xenon Pharmaceuticals (XENE)

• Market cap: $2.78B
• 1 day: -0.61%
• 5 days: -5.61%
• 1 month: -5.86%
• 3 months: 12.4%
• 6 months: 1.1%
• Year to date: -10.41%
• 1 year: -9.98%
• 5 years: 227.18%
• 10 years: 301.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Employees: 327

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 55

17% more call options, than puts

Call options by funds: $11.4M | Put options by funds: $9.75M

8.11% more ownership

Funds ownership: 100.23% [Q1] → 108.34% (+8.11%) [Q2]

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1% more capital invested

Capital invested by funds: $2.58B [Q1] → $2.6B (+$26M) [Q2]

0% less funds holding

Funds holding: 206 [Q1] → 205 (-1) [Q2]

29% less funds holding in top 10

Funds holding in top 10: 14 [Q1] → 10 (-4) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $43
• Avg. target: $50
• High target: $55

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Benjamin Burnett	$48	Overweight Assumed	3 Sep 2025
RBC Capital Brian Abrahams	$55	Outperform Reiterated	2 Sep 2025
Chardan Capital Rudy Li	$55	Buy Maintained	12 Aug 2025
Wedbush Laura Chico	$43	Outperform Maintained	12 Aug 2025